Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (<i>ERBB2</i>)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
During this study period, the most common regimens were platinum-based chemotherapy with or without ICI in first and second line, and median rwOS was 13.2 and 8.2 months, respectively. These results indicate the need for more effective targeted therapies in this patient population.
Authors
- Clara Lam (ORCID: https://orcid.org/0009-0000-8995-2697)
- Zoe L. Jiang (ORCID: https://orcid.org/0000-0002-8944-7444)
- Sarah Waliany (ORCID: https://orcid.org/0000-0001-5960-8801)
- Feng Lin (ORCID: https://orcid.org/0000-0001-8520-0420)
- Joel W. Neal (ORCID: https://orcid.org/0000-0003-3119-9334)
- Misako Nagasaka (ORCID: https://orcid.org/0000-0001-5308-615X)
- Leah Park (ORCID: https://orcid.org/0000-0003-1166-6265)
Institutions
- University of California, Irvine (US)
- Massachusetts General Hospital (US)
- AstraZeneca (United States) (US)
- Daiichi Sankyo (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70272
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca
- Daiichi Sankyo Europe